Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B

Table 1 Baseline characteristics of patients in each group

	Overlap	Non-overlap
Age (yr)	43.3 ± 8.9	43.7 ± 13.0
Male/female ratio	32/8	29/11
Baseline ALT (IU/L)	188.4 ± 74.1	209.6 ± 130.6
Baseline HBV DNA	6.9 ± 0.6	6.9 ± 0.7
(log10 copy/mL)
Median lamivudine treatment (mo)	21.5	20.3
HBeAg positive/negative	22/18	25/15

Table 2 Comparison of mean serum ALT levels in each group

	wk after adefovir treatment (IU/L)
	0	12	24	36	48
Overlap	188.4 ± 74.1	77.3 ± 53.9	78.3 ± 90.2	34.2 ± 13.4	25.9 ± 9.9
Non-overlap	209.6 ± 130.6	78.9 ± 40.8	43.6 ± 24.9	34.2 ± 8.7	24.0 ± 8.7
P-value	NS	NS	NS	NS	NS

NS: Not statistically significant.

Table 3 Comparison of median serum HBV DNA levels in each group

	wk after adefovir treatment (Log10 copies/mL)
	0	12	48
Overlap	6.9 ± 0.6	5.5 ± 1.4	3.8 ± 1.0
Non-overlap	6.9 ± 0.7	4.2 ± 1.2	3.4 ± 1.4
P-value	NS	NS	NS

NS: Not statistically significant.